However, at least a research group has succeeded in developing a novel cyclopeptide from the cyclization of PACAP (1–5) that possesses potent activity towards PAC1 and is able to attenuate experimentally-induced diabetes and ganglionic cell death [82, 83], suggesting that advances have been made to overcome the problems associated with poor peptide availability. The gene discussed is ADCYAP1; the disease is diabetes mellitus.